A+HA Premium Oral Hyaluronic Acid Drink Functional Evaluation Trial for Delaying Joint Pain
調査の概要
詳細な説明
Arthritis is an inflammation of one or more joints that is characterized by pain, stiffness (especially in the early morning or after exercise), swelling, deformation, and/or reduced mobility. Osteoarthritis, also known as degenerative arthritis, is caused by abnormal damage to the cartilage at the ends of bones. Some patients are caused by injury or congenital abnormalities in the proteins that make up cartilage.
Once the cartilage tissue changes from smooth to rough, or into small pieces. Cartilage is gradually destroyed, and the normally smooth surface becomes irregular. Osteoarthritis usually occurs in joints that require weight load, such as the spine, knees, hips and back, and is usually preceded by some pain and Symptoms of stiffness (mostly stiffness first, then pain), but swelling is not necessarily present. However, a small number of them will cause disability, but once the bones become more fragmented, they are more likely to cause fractures. When osteoarthritis is more severe, the bones can overgrow into osteophytes, known as bone spurs. When bone spurs develop, they can be detected with X-rays, usually in the neck or waist near degenerative cartilage. Formation, these phenomena will not produce any changes in appearance.
Osteoarthritis usually does not occur in adults under the age of 40. Most patients are over the age of 60. Symptoms may be so mild that you are unaware of them until detected by X-ray. The incidence is almost higher in women than in men. three times. Degenerative arthritis is increasing among the elderly in Taiwan. It has become a very important health problem and directly affects the quality of life. Pain control can improve the quality of life.
Previous studies have shown that orally administered hyaluronic acid (HA) can bind to toll-like receptor 4 (TLR-4) on intestinal epithelial cells, thereby increasing the secretion of the anti-inflammatory cytokine IL-10 and suppressor of cytokine signaling 3 (SOCS3), while suppressing the expression of the pro-inflammatory cytokine pleiotrophin, ultimately alleviating osteoarthritis. Regarding the regulation of cartilage degradation-related factors, HA can reduce irregularities on the cartilage surface as well as the loss of cartilage tissue and chondrocytes by suppressing the mRNA expression of MMP-3, MMP-9, and MMP-13 in cartilage tissue. In terms of oxidative stress, HA may also alleviate cartilage damage by downregulating inducible nitric oxide synthase (iNOS), thereby reducing nitric oxide (NO) production, and by inhibiting cyclooxygenase-2 (COX-2) and prostaglandin E2 (PGE2) production. To further enhance its efficacy in improving osteoarthritis, hyaluronic acid was combined with glucosamine and chondroitin. Previous studies have demonstrated that these two ingredients can improve connective tissue function and reduce cartilage matrix degradation. Therefore, the aim of this study was to investigate the effects of A+HA premium oral hyaluronic acid drink on improving knee pain.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究場所
-
-
-
Taipei、台湾
- Taipei Medical University
-
コンタクト:
- YiWen Chien, PhD
- 電話番号:+886 2-27361661 #28363
- メール:ychien@tmu.edu.tw
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Aged 45 to 80 years.
- Knee osteoarthritis classified as Ahlbäck stage I or II, or Kellgren-Lawrence grade <3.
- A Visual Analogue Scale (VAS) pain score ≤3.
- A Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale score >2 or a total WOMAC score >12.
Exclusion Criteria:
- Pregnant or breastfeeding women.
- Individuals with a history of knee joint trauma or surgery.
- A body mass index (BMI) ≥ 40 kg/m².
- Individuals with a psychiatric disorder.
- Individuals with severe cardiovascular disease, severe cerebrovascular disease, severe rheumatic disease, crystal deposition arthropathy, or cancer.
- Individuals who use a wheelchair and have a Manual Muscle Testing (MMT) grade ≤3 in the lower extremities, or who require a wheelchair due to physical discomfort.
- Use of anti-inflammatory analgesics, corticosteroids, or other medications that may affect the study outcomes within one week before the trial.
- Receipt of intra-articular corticosteroid injections, hyaluronic acid injections, platelet-rich plasma (PRP) therapy, or nerve block treatment within one month before the trial.
- Use of medications or consumption of foods that, in the judgment of a physician or dietitian, may affect the outcome measures.
- Any other condition considered by the physician to make the individual unsuitable for participation in the trial.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
プラセボコンパレーター:Placebo
Placebo use contents without active ingredients
|
1 drink daily
|
|
実験的:A+HA premium oral hyaluronic acid drink
A+HA premium oral hyaluronic acid drink contains hyaluronic acid, glucosamine hydrochloride, and chondroitin
|
1 drink daily
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Points change of pain evaluation scale
時間枠:From the start to the end of treatment at 12 weeks
|
Self-assess pain using a visual analog scale (VAS), which is a straight line 10 cm in length, with 0 cm on the left representing no pain and 10 cm on the right representing extreme pain.
Explain to the subjects that the pain intensity increases from left to right.
Ask the subjects to mark the point on the line that corresponds to their pain level, and then record the distance in centimeters from the 0 cm mark.
Record the points that the subjects wrote.
|
From the start to the end of treatment at 12 weeks
|
|
Points change of Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
時間枠:From the start to the end of treatment at 12 weeks
|
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), a widely used questionnaires used by health professionals to evaluate the condition of patients with osteoarthritis of the knee and hip, and the total score was 96 points (Minimum: 0 points; Maximum: 96 points).
The question content was divided into three parts: Pain (20 points), Stiffness (8 points), and Physical function (68 points).
The higher score meant worse knee joint function.
Record the points that the subjects got.
|
From the start to the end of treatment at 12 weeks
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Concentration change of aspartate aminotransferase (AST)
時間枠:From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of alanine aminotransferase (ALT)
時間枠:From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of blood glucose
時間枠:From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of high-density lipoprotein
時間枠:From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of low-density lipoprotein
時間枠:From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of free fatty acid
時間枠:From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of cholesterol
時間枠:From the start to the end of the treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of the treatment at 12 weeks
|
|
Concentration change of triglyceride
時間枠:From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Count change of differential count (DC)
時間枠:From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Mean corpuscular volume (MCV)
時間枠:From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of hemoglobin
時間枠:From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of hematocrit
時間枠:From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Red blood cell count
時間枠:From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of gamma-glutamyl transferase (γ-GT)
時間枠:From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of albumin
時間枠:From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of blood urea nitrogen (BUN)
時間枠:From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of creatinine
時間枠:From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of urea acid
時間枠:From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of thyroid-stimulating hormone (TSH)
時間枠:From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of triiodothyronine (T3)
時間枠:From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of thyroxine (T4)
時間枠:From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of sodium (Na)
時間枠:From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of potassium (K)
時間枠:From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of calcium (Ca)
時間枠:From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of magnesium (Mg)
時間枠:From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of phosphorus (P)
時間枠:From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Change of urine pH value
時間枠:From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of urine protein
時間枠:From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of urine glucose
時間枠:From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- N202606002
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。